Revumenib
- Generic Name
- Revumenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47FN6O4S
- CAS Number
- 2169919-21-3
- Unique Ingredient Identifier
- LZ0M43NNF2
- Associated Conditions
- -
- Associated Therapies
- -
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 415
- Registration Number
- NCT06652438
- Locations
- 🇩🇪
DE-Berlin-CAMPUSBENFRANKLIN, Berlin, Germany
🇩🇪DE-Berlin-CAMPUSVIRCHOW, Berlin, Germany
🇩🇪DE-Berlin-VIVANTESNEUKOLLN, Berlin, Germany
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT06575296
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Revumenib in Combination With 7+3 + Midostaurin in AML
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Maximilian Stahl, MD
- Target Recruit Count
- 22
- Registration Number
- NCT06313437
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT06284486
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06229912
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 30
- Registration Number
- NCT06222580
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06177067
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Expanded Access Program for Revumenib
- Conditions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT05918913
- Locations
- 🇺🇸
City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇺🇸Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT05886049
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Conditions
- Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRefractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: CytarabineDrug: Calaspargase PegolProcedure: EchocardiographyDrug: Fludarabine PhosphateDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PrednisoloneDrug: PrednisoneDrug: RevumenibDrug: Vincristine Sulfate
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT05761171
- Locations
- 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.